107 related articles for article (PubMed ID: 1568228)
1. p53 and Kirsten-ras mutations in human mesothelioma cell lines.
Metcalf RA; Welsh JA; Bennett WP; Seddon MB; Lehman TA; Pelin K; Linnainmaa K; Tammilehto L; Mattson K; Gerwin BI
Cancer Res; 1992 May; 52(9):2610-5. PubMed ID: 1568228
[TBL] [Abstract][Full Text] [Related]
2. Genetic alterations of the p53 gene are a feature of malignant mesotheliomas.
Cote RJ; Jhanwar SC; Novick S; Pellicer A
Cancer Res; 1991 Oct; 51(19):5410-6. PubMed ID: 1913660
[TBL] [Abstract][Full Text] [Related]
3. p53 and K-RAS alterations in pancreatic epithelial cell lesions.
Kalthoff H; Schmiegel W; Roeder C; Kasche D; Schmidt A; Lauer G; Thiele HG; Honold G; Pantel K; Riethmüller G
Oncogene; 1993 Feb; 8(2):289-98. PubMed ID: 8426738
[TBL] [Abstract][Full Text] [Related]
4. p53 mutations in bladder carcinoma cell lines.
Cooper MJ; Haluschak JJ; Johnson D; Schwartz S; Morrison LJ; Lippa M; Hatzivassiliou G; Tan J
Oncol Res; 1994; 6(12):569-79. PubMed ID: 7787250
[TBL] [Abstract][Full Text] [Related]
5. State of p53, Rb and DCC tumor suppressor genes in human oral cancer cell lines.
Kim MS; Li SL; Bertolami CN; Cherrick HM; Park NH
Anticancer Res; 1993; 13(5A):1405-13. PubMed ID: 8239512
[TBL] [Abstract][Full Text] [Related]
6. Genetic alterations in K-ras and p53 cancer genes in lung neoplasms from Swiss (CD-1) male mice exposed transplacentally to AZT.
Hong HH; Dunnick J; Herbert R; Devereux TR; Kim Y; Sills RC
Environ Mol Mutagen; 2007; 48(3-4):299-306. PubMed ID: 16395694
[TBL] [Abstract][Full Text] [Related]
7. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines.
Lehman TA; Bennett WP; Metcalf RA; Welsh JA; Ecker J; Modali RV; Ullrich S; Romano JW; Appella E; Testa JR
Cancer Res; 1991 Aug; 51(15):4090-6. PubMed ID: 1855224
[TBL] [Abstract][Full Text] [Related]
8. Molecular events including p53 and k-ras alterations in the in vitro progression of a human colorectal adenoma cell line to an adenocarcinoma.
Williams AC; Browne SJ; Yeudal WA; Paterson IC; Marshall CJ; Lane DP; Paraskeva C
Oncogene; 1993 Nov; 8(11):3063-72. PubMed ID: 8414507
[TBL] [Abstract][Full Text] [Related]
9. K-ras and p53 mutations in hamster pancreatic ductal adenocarcinomas and cell lines.
Erill N; Cuatrecasas M; Sancho FJ; Farré A; Pour PM; Lluís F; Capellá G
Am J Pathol; 1996 Oct; 149(4):1333-9. PubMed ID: 8863680
[TBL] [Abstract][Full Text] [Related]
10. P53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis.
Chang KW; Sarraj S; Lin SC; Tsai PI; Solt D
Carcinogenesis; 2000 Jul; 21(7):1441-51. PubMed ID: 10874024
[TBL] [Abstract][Full Text] [Related]
11. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
[TBL] [Abstract][Full Text] [Related]
12. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.
Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS
Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748
[TBL] [Abstract][Full Text] [Related]
13. Alterations of the p53 tumor suppressor gene during mouse skin tumor progression.
Ruggeri B; Caamano J; Goodrow T; DiRado M; Bianchi A; Trono D; Conti CJ; Klein-Szanto AJ
Cancer Res; 1991 Dec; 51(24):6615-21. PubMed ID: 1742735
[TBL] [Abstract][Full Text] [Related]
14. Activation of K-ras by codon 13 mutations in C57BL/6 X C3H F1 mouse tumors induced by exposure to 1,3-butadiene.
Goodrow T; Reynolds S; Maronpot R; Anderson M
Cancer Res; 1990 Aug; 50(15):4818-23. PubMed ID: 2196119
[TBL] [Abstract][Full Text] [Related]
15. Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations.
Hollstein MC; Peri L; Mandard AM; Welsh JA; Montesano R; Metcalf RA; Bak M; Harris CC
Cancer Res; 1991 Aug; 51(15):4102-6. PubMed ID: 1855226
[TBL] [Abstract][Full Text] [Related]
16. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study.
Slebos RJ; Hoppin JA; Tolbert PE; Holly EA; Brock JW; Zhang RH; Bracci PM; Foley J; Stockton P; McGregor LM; Flake GP; Taylor JA
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1223-32. PubMed ID: 11097231
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of p53 gene mutations in the supernatant of bile for diagnosis of biliary tract carcinoma: comparison with K- ras mutation.
Wang Y; Yamaguchi Y; Watanabe H; Ohtsubo K; Wakabayashi T; Sawabu N
J Gastroenterol; 2002; 37(10):831-9. PubMed ID: 12424567
[TBL] [Abstract][Full Text] [Related]
18. Concomitant point mutation of tumor suppressor gene p53 and oncogene c-N-ras in malignant neuroendocrine pancreatic tumor.
Hrasćan R; Pavelić K; Pavicić D; Krizanac S; Stajcer-Sittić V; Pecur L; Spaventi S; Klimpfinger M; Pavelić J
Anticancer Res; 1996; 16(6B):3761-6. PubMed ID: 9042254
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.
Akkiprik M; Ataizi-Celikel C; Düşünceli F; Sönmez O; Gulluoglu BM; Sav A; Ozer A
J Gastrointestin Liver Dis; 2007 Mar; 16(1):11-7. PubMed ID: 17410283
[TBL] [Abstract][Full Text] [Related]
20. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women.
Gealy R; Zhang L; Siegfried JM; Luketich JD; Keohavong P
Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 1):297-302. PubMed ID: 10207632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
